Growth hormone replacement throughout life: Insights into age-related responses to treatment

被引:36
作者
Clayton, Peter
Gleeson, Helena
Monson, John
Popovic, Vera
Shalet, Stephen M.
Christiansen, J. Sandahl [1 ]
机构
[1] Aarhus Univ Hosp, Kommunehosp, Dept Endocrinol, DK-8000 Aarhus, Denmark
[2] Univ Manchester, Sch Med, Div Human Dev, Endocrine Sci Res Grp, Manchester, Lancs, England
[3] Christie Hosp, Dept Endocrinol, Manchester, Lancs, England
[4] Univ London, Queen Marys Sch Med & Dent, St Bartholomews Hosp, Ctr Clin Endocrinol,William Harvey Res Inst, London, England
[5] Univ Clin Ctr, Inst Endocrinol, Belgrade, Serbia
关键词
adult; growth hormone deficiency; transition; middle age; elderly; growth; cardiovascular; quality of life;
D O I
10.1016/j.ghir.2007.04.010
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
The adult growth hormone deficiency (GHD) syndrome is a well-defined clinical entity. Although the symptoms of GHD are not age specific, their relative importance differs depending on the patient's age, and the impact of GHD varies throughout adult life. Ceasing growth hormone (GH) therapy soon after final height in patients with severe GHD potentially limits somatic development by reducing accrual of bone and muscle mass. It is now recognized that the continuation of GH therapy in the transition years is required to achieve adult levels of somatic development. In middle age, the most worrying feature of GHD is the increase in cardiovascular risk, an important component of which is GHD-related dyslipidemia. One of the most profound effects of GH therapy in this age group is the durable reduction in cholesterol levels. Elderly GH-deficient patients experience the symptoms of GHD over and above the signs of normal aging. Perhaps most importantly, these patients have impaired quality of life, with fatigue as a major component. Evidence is growing for improved quality of life with GH therapy in the elderly. This review describes the diagnosis, symptoms and treatment of GHD specific to the different age groups. (c) 2007 Published by Elsevier Ltd.
引用
收藏
页码:369 / 382
页数:14
相关论文
共 87 条
[1]   Isolated growth hormone (GH) deficiency in adult patients:: Baseline clinical characteristics and responses to GH replacement in comparison with hypopituitary patients.: A sub-analysis of the KIMS database [J].
Abs, R ;
Mattsson, AF ;
Bengtsson, BÅ ;
Feldt-Rasmussen, U ;
Góth, MI ;
Koltowska-Häggström, M ;
Monson, JP ;
Verhelst, J ;
Wilton, P .
GROWTH HORMONE & IGF RESEARCH, 2005, 15 (05) :349-359
[2]   GH replacement in 1034 growth hormone deficient hypopituitary adults:: demographic and clinical characteristics, dosing and safety [J].
Abs, R ;
Bengtsson, BÅ ;
Hernberg-Ståhl, E ;
Monson, JP ;
Tauber, JP ;
Wilton, P ;
Wüster, C .
CLINICAL ENDOCRINOLOGY, 1999, 50 (06) :703-713
[3]   Update on the diagnosis of GH deficiency in adults [J].
Abs, R .
EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2003, 148 :S3-S8
[4]  
ABS R, 2004, GROWTH HORMONE DEFIC
[5]   Determinants of cardiovascular risk in 2589 hypopituitary GH-deficient adults -: a KIMS database analysis [J].
Abs, Roger ;
Feldt-Rasmussen, Ulla ;
Mattsson, Anders F. ;
Monson, John P. ;
Bengtsson, Bengt-Ake ;
Goth, Miklos I. ;
Wilton, Patrick ;
Koltowska-Haggstrom, Maria .
EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2006, 155 (01) :79-90
[6]   Different degrees of GH deficiency evidenced by GHRH plus arginine test and IGF-I levels in adults with pituritary disease [J].
Aimaretti, G ;
Corneli, G ;
Di Somma, C ;
Baldelli, R ;
Gasco, V ;
Rovere, S ;
Migliaretti, G ;
Colao, A ;
Tamburrano, G ;
Lombardi, G ;
Ghigo, E ;
Camanni, F .
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 2005, 28 (03) :247-252
[7]   BODY-COMPOSITION, BONE METABOLISM, AND HEART STRUCTURE AND FUNCTION IN GROWTH-HORMONE (GH)DEFICIENT ADULTS BEFORE AND AFTER GH REPLACEMENT THERAPY AT LOW-DOSES [J].
AMATO, G ;
CARELLA, C ;
FAZIO, S ;
LAMONTAGNA, G ;
CITTADINI, A ;
SABATINI, D ;
MARCIANOMONE, C ;
SACCA, L ;
BELLASTELLA, A .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1993, 77 (06) :1671-1676
[8]  
Attanasio A, 1998, J CLIN ENDOCR METAB, V83, P379
[9]   Quality of life in childhood onset growth hormone-deficient patients in the transition phase from childhood to adulthood [J].
Attanasio, AF ;
Shavrikova, EP ;
Blum, WF ;
Shalet, SM .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2005, 90 (08) :4525-4529
[10]   Continued growth hormone (GH) treatment after final height is necessary to complete somatic development in childhood-onset GH-deficient patients [J].
Attanasio, AF ;
Shavrikova, E ;
Blum, WF ;
Cromer, M ;
Child, CJ ;
Paskova, M ;
Lebl, J ;
Chipman, JJ ;
Shalet, SM .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2004, 89 (10) :4857-4862